Report Description Table of Contents What Is the Current Sjögren’s Syndrome Treatment Market Size and How Is the Therapeutic Landscape Changing? The Global Sjögren’s Syndrome Treatment Market was valued at USD 0.62 billion in 2025 and is projected to reach USD 0.95 billion by 2032, expanding at a CAGR of 6.3% during 2026–2032, according to Strategic Market Research. Sjögren disease (SjD) therapeutics market is advancing through targeted immune-modulating technologies addressing B-cell activity, autoantibody production, and inflammatory pathways. Novartis is developing ianalumab, a BAFF-R–targeting B-cell depletion antibody, while RemeGen/Vor Bio advances telitacicept, a BLyS/APRIL dual-target fusion protein. Johnson & Johnson is evaluating nipocalimab, an FcRn blocker technology, and AstraZeneca applies B-cell depletion approaches. Emerging platforms include CD40 pathway inhibition (iscalimab) and immune co-stimulation modulation (dacidilimab), expanding the pipeline for disease-specific treatment options. The Sjögren’s disease market is driven by a substantial yet underdiagnosed autoimmune patient population and significant unmet treatment needs. In the United States, estimates suggest that 500,000 to 2 million people have been diagnosed, while advocacy organizations estimate that up to 4 million individuals may be affected. The diagnosed prevalence increased from 195.95 to 259.20 cases per 100,000 people between 2019 and 2023, reflecting greater disease recognition and diagnosis. Globally, primary Sjögren’s disease affects approximately 61 people per 100,000, and women account for nearly 90% of diagnosed adults, underscoring the potential for targeted therapies in this concentrated patient population. Sjögren’s Syndrome Treatment Market Snapshot: Revenue, Growth and Segment Priorities By Syndrome Type Primary Sjögren’s Syndrome: Accounted for 73.0% of the market at USD 0.453 billion in 2025 and is projected to expand at a 6.6% CAGR, supported by its central role in disease-specific clinical development and treatment pathways. Secondary Sjögren’s Syndrome / Associated Sjögren Disease: Represented 27.0% at USD 0.167 billion and a 5.4% CAGR; current international nomenclature favors “associated Sjögren disease” when SjD coexists with another systemic autoimmune disease. [9] By Drug Class Cholinergic Agonists: Held 22.5% of the market at USD 0.140 billion in 2025 and a 5.8% CAGR, reflecting the established role of pilocarpine and cevimeline in persistent xerostomia. Antimalarial Quinolines: Accounted for 16.2% at USD 0.100 billion and a 5.2% CAGR, with hydroxychloroquine retaining a substantial clinical footprint despite limited randomized evidence for core Sjögren symptoms. Corticosteroids: Represented 14.8% at USD 0.092 billion and a 4.8% CAGR, supported by frequent use in inflammatory flares and systemic disease but constrained by chronic toxicity and generic pricing. Immunosuppressants: Held 13.6% at USD 0.084 billion and a 6.0% CAGR, serving steroid-sparing and organ-involved treatment pathways. Biologics & Targeted Therapies: Accounted for 12.4% at USD 0.077 billion and lead segment growth at an 11.4% CAGR; the 2025 revenue base reflects existing advanced systemic treatment, while future growth is increasingly linked to disease-specific approvals and late-stage pipeline conversion. NSAIDs & Pain Relievers: Represented 11.7% at USD 0.073 billion and a 4.3% CAGR, maintaining a supportive role in arthralgia, myalgia and inflammatory discomfort. Others: Held 8.8% at USD 0.055 billion and a 6.4% CAGR, covering smaller supportive and less frequently used pharmacologic approaches within the supplied SMR market taxonomy. By Route of Administration Oral: Held 58.5% of the market at USD 0.363 billion in 2025 and a 5.4% CAGR because most established symptom-control and systemic maintenance therapies are orally administered. Ophthalmic/Topical: Accounted for 24.8% at USD 0.154 billion and a 6.5% CAGR, supported by recurring local management of ocular and mucosal dryness that can persist despite systemic disease control. Parenteral: Represented 12.2% at USD 0.076 billion and is projected to expand at a 10.0% CAGR as injectable and infused biologic therapy gains strategic importance. Others: Held 4.5% at USD 0.028 billion and a 5.2% CAGR, serving narrower individualized administration requirements. By Distribution Channel Hospital Pharmacies: Accounted for 31.8% at USD 0.197 billion in 2025 and a 6.3% CAGR, reflecting specialist-managed systemic disease and advanced therapy use. Retail Pharmacies & Drug Stores: Led with 51.5% at USD 0.319 billion and a 5.5% CAGR because current treatment remains dominated by oral maintenance and symptom-control prescriptions. Online Pharmacies: Represented 16.7% at USD 0.104 billion and an 8.5% CAGR, supported by refill-based chronic therapy and home-delivery models. By Geography North America: Held 40.2% of the market at USD 0.249 billion in 2025 and is projected to expand at a 6.1% CAGR. Europe: Accounted for 29.4% at USD 0.182 billion and a 5.7% CAGR. Asia-Pacific: Represented 22.3% at USD 0.138 billion and leads regional growth at a 7.3% CAGR, with China now providing the first commercial proof point for disease-specific systemic treatment. Latin America: Held 5.0% at USD 0.031 billion and is projected to expand at a 6.5% CAGR. Middle East & Africa: Accounted for 3.1% at USD 0.019 billion and a 5.9% CAGR. Sjögren’s Syndrome Treatment Market Revenue Architecture: Established Therapies Versus Targeted Expansion Primary Sjögren’s Syndrome accounted for 73.0% of the market, representing USD 0.453 billion in 2025, and is projected to expand at a CAGR of 6.6% during 2026–2032. Its leading position is consistent with the larger representation of stand-alone SjD in treatment datasets and with disease-specific clinical programs that enroll patients whose Sjögren disease is the principal autoimmune condition. In the supplied U.S. treatment cohort, 67.2% of the 35,035 newly diagnosed patients had SjD without another overlapping autoimmune condition. Pipeline activity such as Vor Bio’s global telitacicept program and Novartis’ ianalumab program is therefore commercially centered on this core disease population. [2][3][5] Secondary Sjögren’s Syndrome, described as associated Sjögren disease in current international nomenclature, represented 27.0% of the market, or USD 0.167 billion in 2025, and is projected to grow at a CAGR of 5.4%. Treatment economics differ because rheumatoid arthritis, systemic lupus erythematosus and other autoimmune diseases can already drive immunosuppressive prescribing, making it harder to attribute every therapy dollar solely to Sjögren. A French national claims study covering 2011–2018 identified 23,848 patients with primary Sjögren and 14,809 with Sjögren associated with another autoimmune disorder, confirming that the associated-disease population is clinically substantial even though revenue can overlap broader autoimmune therapy. [9][10] Cholinergic agonists held the largest drug-class share at 22.5%, equivalent to USD 0.140 billion in 2025, and are projected to grow at a CAGR of 5.8%. Pilocarpine and cevimeline remain commercially durable because they directly stimulate residual salivary function and have U.S. labeled indications for Sjögren-related dry-mouth symptoms. Their position is unlikely to disappear simply because systemic biologics improve: patients with established glandular dysfunction can continue to require local symptom control, creating a complementary rather than purely substitutive relationship between secretagogues and future disease-modifying therapy. [4][5] Antimalarial quinolines accounted for 16.2% of the market, representing USD 0.100 billion in 2025, and are projected to expand at a CAGR of 5.2%. Hydroxychloroquine remains embedded in rheumatology practice and was used by 29.0% of newly diagnosed U.S. patients in the supplied real-world analysis, but the pivotal JOQUER randomized trial found the 24-week primary symptom response in 17.9% of hydroxychloroquine-treated patients versus 17.2% with placebo. The gap between clinical familiarity and limited randomized efficacy for dryness, pain and fatigue creates a clear replacement opportunity for targeted therapies that can demonstrate reproducible systemic and patient-reported benefit. [2][11] Corticosteroids represented 14.8% of the market, valued at USD 0.092 billion in 2025, and are projected to grow at a CAGR of 4.8%. Their revenue share understates their clinical footprint because these low-cost generics are frequently used for inflammatory flares and organ manifestations; the supplied U.S. analysis reported systemic corticosteroid use in 42.8% of newly diagnosed patients. The segment’s slower growth is commercially consistent with long-term safety limitations and the strategic goal of newer therapies to provide steroid-sparing disease control rather than simply add another chronic corticosteroid regimen. [2] Immunosuppressants accounted for 13.6% of the market, equivalent to USD 0.084 billion in 2025, and are projected to expand at a CAGR of 6.0%. Methotrexate, azathioprine, mycophenolate and related agents are used mainly when disease extends beyond dryness into systemic inflammatory or organ involvement. Their broad physician familiarity and generic pricing make them an important reimbursement comparator: premium biologics will need to justify higher cost through durable systemic benefit, reduced corticosteroid exposure, meaningful symptom improvement or stronger control of organ-level disease. Biologics and targeted therapies represented 12.4% of the market, valued at USD 0.077 billion in 2025, and are projected to grow fastest at an 11.4% CAGR. This is the market’s most important mix-shift. The 2025 category should be read as existing advanced systemic and biologic expenditure and should not be attributed to late-stage assets as if they were already approved disease-specific Sjögren therapies in 2025. The forward growth case is driven by transition toward indication-specific branded therapy: telitacicept is now approved in China, ianalumab is under priority regulatory review in the U.S., and nipocalimab and dazodalibep are in Phase III development. Successful conversion of these programs would increase the share of market value attributable to specialty immunology products rather than generic symptomatic or broad immunosuppressive therapy. [3][6][7] NSAIDs and pain relievers accounted for 11.7% of the market, representing USD 0.073 billion in 2025, and are projected to expand at a CAGR of 4.3%. These products mainly address arthralgia, myalgia and inflammatory discomfort and generally do not modify the underlying autoimmune process. Their commercial role should therefore remain supportive, including in patients who later receive targeted systemic treatment. Other drug classes held 8.8% of the market, valued at USD 0.055 billion in 2025, and are projected to grow at a CAGR of 6.4%. This category is intentionally kept broad in the supplied SMR taxonomy and captures smaller supportive and less frequently used pharmacologic approaches; it should not be interpreted as a single homogeneous therapeutic class. From Secretagogues to Specialty Immunology: The Changing Treatment and Distribution Mix Oral therapies accounted for 58.5% of the market, representing USD 0.363 billion in 2025, and are projected to expand at a CAGR of 5.4%. The route’s leading share reflects the current treatment architecture: pilocarpine, cevimeline, hydroxychloroquine, corticosteroids, NSAIDs and many conventional immunosuppressants can be maintained without infusion infrastructure. Oral therapy should remain the market’s volume backbone even if its revenue share gradually gives way to higher-value parenteral products. Ophthalmic and topical therapies held 24.8% of the market, valued at USD 0.154 billion in 2025, and are projected to grow at a CAGR of 6.5%. Persistent ocular and mucosal dryness creates recurring local treatment use, and NIAMS continues to describe artificial tears, prescription eye treatments, ointments and saliva-support approaches as part of routine Sjögren management. This route is commercially resilient because improved systemic control does not necessarily reverse established exocrine-gland dysfunction. [12] Parenteral therapies represented 12.2% of the market, equivalent to USD 0.076 billion in 2025, and are projected to expand at a 10.0% CAGR. The growth rate closely tracks the market’s migration toward biologics and targeted systemic therapy. Products acting on B-cell survival, FcRn-mediated IgG recycling or immune co-stimulation shift part of expenditure toward specialist prescribing, specialty-drug handling and payer authorization, creating higher revenue intensity per treated patient than many current oral generics. [3][6][7] Other administration routes accounted for 4.5% of the market, representing USD 0.028 billion in 2025, with a projected CAGR of 5.2%. Their role remains narrower and reflects individualized management rather than a major shift in the treatment pathway. Retail pharmacies and drug stores held the largest distribution share at 51.5%, equivalent to USD 0.319 billion in 2025, and are projected to expand at a CAGR of 5.5%. This position follows directly from the current oral and symptom-directed treatment mix. Hospital pharmacies accounted for 31.8% at USD 0.197 billion and a 6.3% CAGR, retaining strategic importance for specialist-managed systemic disease and advanced therapies. Online pharmacies represented 16.7% at USD 0.104 billion and are projected to grow at an 8.5% CAGR as refill-based chronic therapy becomes more compatible with digital prescription and home-delivery models. Specialty-pharmacy activity is not presented as a separate segment in the supplied SMR distribution taxonomy, which becomes increasingly relevant as biologic penetration rises. Sjögren’s Syndrome Treatment Market by Region: China Leads the First Approval Wave While the U.S. and Europe Prepare for Targeted Therapy North America accounted for 40.2% of the Sjögren’s Syndrome Treatment Market, representing USD 0.249 billion in 2025, and is projected to expand at a CAGR of 6.1%. The region combines high specialty-drug spending, established rheumatology infrastructure and an increasingly visible diagnosed population. The 2025 U.S. claims analysis found diagnosed prevalence rose from 195.95 per 100,000 in 2019 to 259.20 per 100,000 in 2023. Commercially, the U.S. is the key test of whether disease-specific systemic therapy can move patients from inexpensive generic treatment into premium immunology products; ianalumab’s Priority Review and the U.S. presence of Phase III programs from Amgen, Johnson & Johnson and Vor Bio make regulatory timing, payer coverage and treatment eligibility more important than simple disease prevalence alone. [1][6][7][17] Europe held 29.4% of the market, equivalent to USD 0.182 billion in 2025, and is projected to grow at a CAGR of 5.7%. The region combines mature specialist care with evidence of diagnostic leakage. A French national claims study covering 2011–2018 identified 23,848 primary Sjögren patients and 14,809 patients with associated autoimmune disease, while Spain’s EPISER 2016 population study estimated overall Sjögren prevalence at 0.33% and primary Sjögren prevalence at 0.25%; only 50% of identified cases had already been diagnosed. Novartis has submitted ianalumab in Europe, so the commercial opportunity includes both deeper treatment of diagnosed systemic patients and the possibility that improved disease recognition enlarges the eligible treatment pool over time. [10][19][6] Asia-Pacific represented 22.3% of the market, valued at USD 0.138 billion in 2025, and is projected to expand at the fastest regional CAGR of 7.3%. China is now the market’s most important regional proof point because telitacicept became the first approved disease-specific Sjögren therapy there in June 2026, giving RemeGen an early commercialization advantage. Japan also has a long-established specialist treatment base, although its most comprehensive national utilization dataset is historical: a Ministry of Health-supported 2011 survey estimated 68,483 patients and reported corticosteroid use in 34%, immunosuppressants in 16%, biologics in 3% and secretagogues in 32% of 2,195 characterized patients. The age of that survey should be considered when interpreting current utilization, but it documents a substantial established treatment pathway into which newer systemic products may enter. [3][20] Latin America held 5.0% of the market, representing USD 0.031 billion in 2025, and is projected to expand at a CAGR of 6.5%. The revenue base is smaller and access to advanced treatment remains more concentrated in specialist centers, so the pace of branded biologic adoption is likely to depend more on diagnostic capacity and reimbursement than on early regulatory timing. Participation of Latin American centers in multinational development programs can nevertheless improve physician familiarity with emerging disease-specific therapies before wider commercialization. The Middle East & Africa accounted for 3.1% of the market, valued at USD 0.019 billion in 2025, and is projected to grow at a CAGR of 5.9%. Current expenditure is concentrated in larger urban health systems and specialist rheumatology settings, with oral and symptomatic medicines retaining a larger role than premium targeted therapy. Market expansion should remain selective until diagnosis, specialist access and specialty-drug funding become more consistent across individual countries. Competitive Positioning in the Sjögren’s Syndrome Treatment Market Amgen Inc. / Horizon Therapeutics: Developing dazodalibep (VIB4920), an immunomodulatory therapy designed to target underlying immune dysfunction and provide a potential disease-modifying treatment option for Sjögren’s disease. Johnson & Johnson: Advancing nipocalimab, an FcRn-targeting therapy aimed at reducing pathogenic antibody activity and addressing autoimmune mechanisms involved in Sjögren’s disease. Bristol Myers Squibb: Evaluating targeted immunology approaches, including deucravacitinib and other pipeline assets, to address inflammatory pathways associated with autoimmune disorders such as Sjögren’s syndrome. Immunovant Sciences: Developing IMVT-1402, an FcRn inhibitor designed to regulate autoimmune antibody-driven responses across multiple immune-mediated diseases, including potential Sjögren’s applications. Resolve Therapeutics: Developing RSLV-132, a biologic therapy focused on reducing systemic autoimmune symptoms and improving outcomes for patients with Sjögren’s disease. Novartis AG: Leading development of ianalumab (VAY736), a BAFF receptor-targeting therapy that regulates B-cell activity and represents one of the most advanced potential disease-modifying approaches in Sjögren’s treatment. Dompé Farmaceutici: Focuses on ocular complications of Sjögren’s syndrome through specialized ophthalmic therapies, including treatments for severe dry-eye and corneal surface damage. OSE Immunotherapeutics / Servier: Developing lusvertikimab (OSE-127), an immune-targeting therapy being investigated for autoimmune and inflammatory conditions. GSK plc: Maintains a broad autoimmune disease pipeline focused on biologic and targeted therapies addressing immune-mediated inflammatory disorders. ADVANZ Pharma: Commercializes symptomatic therapies such as SALAGEN (pilocarpine) to manage xerostomia (dry mouth), one of the primary symptoms associated with Sjögren’s syndrome. Sylentis: Develops RNA interference-based ophthalmic treatments, including tivanisiran, targeting ocular manifestations linked to dry-eye disease. RemeGen Co., Ltd.: Developed telitacicept, a dual BLyS/APRIL-targeting fusion protein designed to regulate B-cell activity and advance disease-modifying treatment options for Sjögren’s syndrome. Daiichi Sankyo Company, Limited: Provides established symptomatic treatment options such as EVOXAC (cevimeline) for dry-mouth management in Sjögren’s patients. Santen Pharmaceutical Co., Ltd.: Specializes in ophthalmic therapies addressing severe dry-eye complications, supporting management of ocular symptoms associated with Sjögren’s disease. Otsuka Holdings Co., Ltd. / Takeda Pharmaceutical Company Limited: Participate in immunology research and autoimmune disease development programs, exploring future therapeutic opportunities in immune-mediated disorders. Vor Bio: Supports global clinical development efforts for advanced biologic therapies such as telitacicept through international collaborations. AbbVie Inc.: Maintains a strong autoimmune disease portfolio with biologic and targeted therapies addressing systemic inflammation and immune dysfunction. F. Hoffmann-La Roche Ltd: Develops immune-targeted therapies focused on B-cell biology and inflammatory pathways relevant to systemic autoimmune diseases, including Sjögren’s syndrome. Analyst Commentary: Sjögren’s Syndrome Market — The Race for Disease-Modifying Leadership Begins The Sjögren’s syndrome treatment market is entering a breakthrough phase where the next major value creation will come from therapies that can modify disease biology rather than simply manage dryness and pain symptoms. While conventional treatments such as secretagogues, corticosteroids, and hydroxychloroquine will continue to support a large patient base, their limited impact on underlying autoimmune mechanisms creates a significant opportunity for targeted immune therapies. Among emerging technologies, B-cell targeted approaches appear best positioned to define the next generation of Sjögren’s treatment. Novartis’ ianalumab, a BAFF-R–targeting B-cell depletion therapy, currently stands out as a potential market-leading asset because it directly addresses one of the central drivers of Sjögren’s pathology: abnormal B-cell activation and autoantibody production. If clinical data demonstrate meaningful improvements in systemic symptoms and quality of life, ianalumab could become the first true disease-modifying therapy and shift treatment standards toward specialty immunology. Telitacicept (RemeGen/Vor Bio) represents another high-potential platform by simultaneously blocking BLyS and APRIL pathways, potentially offering deeper control of antibody-producing immune cells. Meanwhile, FcRn inhibitors such as nipocalimab could become important for patients with antibody-driven disease by reducing pathogenic IgG activity without directly eliminating immune cells. The longer-term disruptor could be immune-reset technologies such as cellular therapies, although commercial adoption remains distant. Overall, the market is likely to evolve into a precision immunology landscape where different mechanisms address different patient subgroups. In the near term, ianalumab appears best positioned to capture first-mover advantage, while telitacicept and FcRn-based therapies could create strong competitive niches. The ultimate winners will be companies that demonstrate not just immune suppression, but durable disease control. Sjögren’s Syndrome Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026–2032 Market Size Value in 2025 USD 0.62 Billion Revenue Forecast in 2032 USD 0.95 Billion Overall Growth Rate 6.3% CAGR Base Year for Estimation 2025 Historical Data 2019–2024 Unit USD Billion Segmentation Syndrome Type, Drug Class, Route of Administration, Distribution Channel, and Geography By Syndrome Type Primary Sjögren’s Syndrome and Secondary Sjögren’s Syndrome / Associated Sjögren Disease By Drug Class Cholinergic Agonists, Antimalarial Quinolines, Corticosteroids, Immunosuppressants, Biologics & Targeted Therapies, NSAIDs & Pain Relievers, and Others By Route of Administration Oral, Ophthalmic/Topical, Parenteral, and Others By Distribution Channel Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies By Region North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Country Scope United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Saudi Arabia, United Arab Emirates, and South Africa Market Drivers Growing disease recognition, underdiagnosed autoimmune populations, recurring dryness management, demand for steroid-sparing treatment, expansion of biologics and targeted immune therapies, disease-specific approvals, specialty-pharmacy utilization, and advancing B-cell and FcRn-targeted clinical programs Customization Option Available upon request Frequently Asked Question About This Report Q1. What are the main factors driving market growth? A1. Growth is being supported by improving diagnosis, a large underrecognized patient population, persistent unmet need in systemic disease, and increasing development of targeted immune therapies. The transition from symptom control toward disease-specific treatment is the most important revenue catalyst. Q2. What is driving the shift toward advanced solutions in the industry? A2. Current treatment relies heavily on secretagogues, corticosteroids, hydroxychloroquine, and conventional immunosuppressants, which have limited ability to control the underlying autoimmune process. This is creating demand for therapies targeting B-cell survival, pathogenic antibodies, and immune co-stimulation. Q3. What new developments are expected to influence the market? A3. Telitacicept’s approval in China and regulatory progress for ianalumab are important near-term developments. Phase III programs involving nipocalimab and dazodalibep could further expand the disease-specific treatment landscape if they demonstrate meaningful systemic benefit. Q4. What are the most promising applications expected to grow in the industry? A4. Targeted systemic treatment for primary disease represents the strongest opportunity, particularly among patients with significant systemic activity or inadequate control with conventional therapies. Parenteral biologics are also positioned to gain value as disease-specific immunology products enter clinical practice. Q5. What strategies are companies adopting to strengthen their position in the market? A5. Companies are pursuing differentiated immune mechanisms such as BAFF-R inhibition, BLyS/APRIL blockade, FcRn inhibition, and co-stimulation modulation. Successful developers will also need strong regulatory evidence, specialist access, payer positioning, and clear patient-selection strategies. Q6. Which region currently leads the industry and why? A6. North America leads because of high specialty-drug spending, established rheumatology infrastructure, increasing disease recognition, and substantial late-stage clinical development. The U.S. is also likely to be a critical test market for reimbursement and adoption of premium disease-specific therapies. Q7. What are the biggest challenges affecting market expansion? A7. Diagnosis can be delayed, disease severity is heterogeneous, and many existing treatments are inexpensive generics. New biologics must therefore demonstrate durable improvements in systemic disease, symptoms, quality of life, or steroid reduction to justify premium pricing and payer coverage. Q8. Why are companies investing in this technology? A8. The market has a substantial treatment gap between symptomatic care and true disease modification. A successful targeted therapy could shift significant value toward specialty immunology while establishing an early leadership position in a therapeutic area with few disease-specific systemic options. Sources: [1] ACR Convergence 2025 - Prevalence of Sjögren’s Disease in the United States, 2019–2023. Open source [2] ACR Convergence 2025 - Real World Treatment Patterns and Health Care Resource Use in Newly Diagnosed Sjögren’s Disease. Open source [3] Vor Bio / RemeGen - Telitacicept Receives NMPA Approval for Sjögren’s Disease in China, 8-Jun-2026. Open source [4] DailyMed - Pilocarpine hydrochloride tablets, Sjögren dry-mouth indication. Open source [5] DailyMed - Cevimeline hydrochloride capsules, Sjögren dry-mouth indication. Open source [6] Novartis Q1 2026 - Ianalumab FDA Breakthrough Therapy designation, Priority Review and multinational submissions. Open source [7] Amgen Q2 2026 - Dazodalibep Phase III Sjögren program. Open source [8] Spotlight on Sjögren’s - 2026 patient burden and treatment satisfaction survey. Open source [9] Nature Reviews Rheumatology - International Rome consensus for Sjögren disease nomenclature, published 2025. Open source [10] RMD Open - French national claims study of Sjögren prevalence, incidence and healthcare costs. Open source [11] JAMA / PubMed - JOQUER randomized clinical trial of hydroxychloroquine. Open source [12] NIH/NIAMS - Sjögren’s Disease: Diagnosis, Treatment, and Steps to Take. Open source [13] Novartis - NEPTUNUS-1 and NEPTUNUS-2 Phase III ianalumab results. Open source [14] ClinicalTrials.gov NCT06104124 - Dazodalibep Phase III, systemic disease activity. Open source [15] ClinicalTrials.gov NCT06245408 - Dazodalibep Phase III, symptom-state population. Open source [16] Johnson & Johnson - Nipocalimab Sjögren biomarker analysis and FDA designations, 3-Jun-2026. Open source [17] ClinicalTrials.gov NCT06741969 - Nipocalimab Phase III DAFFODIL program. Open source [18] Monte Rosa Therapeutics Q2 2026 / SEC filing - MRT-6160 (DDY391) Phase II Sjögren activation. Open source [19] Scientific Reports - Spain EPISER study of Sjögren prevalence and undiagnosed cases. Open source [20] PubMed - Japanese national Sjögren epidemiology and treatment survey. Open source [21] Amgen Q1 2026 - AMG 329 Sjögren Phase II futility decision. Open source Table of Contents - Global Sjögren’s Syndrome Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Syndrome Type, Drug Class, Route of Administration, Distribution Channel, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Syndrome Type, Drug Class, Route of Administration, Distribution Channel, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Syndrome Type, Drug Class, Route of Administration, and Distribution Channel Investment Opportunities in the Sjögren’s Syndrome Treatment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Disease-Modifying Therapies, B-Cell Targeted Therapies, FcRn Inhibitors, Secretagogues, Ophthalmic Treatments, and Systemic Autoimmune Disease Management Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Sjögren’s Syndrome Treatment in Dryness Management, Systemic Autoimmune Care, and Disease-Modifying Therapeutics Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Reimbursement Factors on Sjögren’s Syndrome Treatment Development and Adoption Role of B-Cell Depletion, BAFF-R Targeting, BLyS/APRIL Inhibition, FcRn Blockade, Immune Co-Stimulation Modulation, and Ophthalmic Therapy in Market Expansion Diagnostic Recognition, Underdetection, Patient Stratification, and Long-Term Disease Management Trends in Sjögren’s Syndrome Global Sjögren’s Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Syndrome Type: Primary Sjögren’s Syndrome Secondary Sjögren’s Syndrome / Associated Sjögren Disease Market Analysis by Drug Class: Cholinergic Agonists Antimalarial Quinolines Corticosteroids Immunosuppressants Biologics & Targeted Therapies NSAIDs & Pain Relievers Others Market Analysis by Route of Administration: Oral Ophthalmic/Topical Parenteral Others Market Analysis by Distribution Channel: Hospital Pharmacies Retail Pharmacies & Drug Stores Online Pharmacies Market Analysis by Geography: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Sjögren’s Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Syndrome Type, Drug Class, Route of Administration, and Distribution Channel Country-Level Breakdown: United States Canada Mexico Europe Sjögren’s Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Syndrome Type, Drug Class, Route of Administration, and Distribution Channel Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Sjögren’s Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Syndrome Type, Drug Class, Route of Administration, and Distribution Channel Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Sjögren’s Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Syndrome Type, Drug Class, Route of Administration, and Distribution Channel Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Sjögren’s Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Syndrome Type, Drug Class, Route of Administration, and Distribution Channel Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Amgen Inc. / Horizon Therapeutics Johnson & Johnson Bristol Myers Squibb Immunovant Sciences Resolve Therapeutics Novartis AG Dompé Farmaceutici OSE Immunotherapeutics / Servier GSK plc ADVANZ Pharma Sylentis RemeGen Co., Ltd. Daiichi Sankyo Company, Limited Santen Pharmaceutical Co., Ltd. Otsuka Holdings Co., Ltd. / Takeda Pharmaceutical Company Limited Vor Bio AbbVie Inc. F. Hoffmann-La Roche Ltd AstraZeneca plc BeiGene, Ltd. argenx SE Alpine Immune Sciences, Inc. Competitive Landscape and Strategic Insights Benchmarking Based on Mechanism of Action, Clinical Development Stage, Regulatory Progress, Therapeutic Differentiation, Specialty-Care Reach, and Regional Presence Pipeline Qualification and Clinical Development Capability Analysis Disease-Modifying Therapy Positioning B-Cell Targeted Therapy and Immune Modulation Competitiveness Secretagogue, Ophthalmic, and Symptom-Control Treatment Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Syndrome Type, Drug Class, Route of Administration, Distribution Channel, and Geography (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Clinical Pipeline, Regulatory Progress, and Commercialization Risk Analysis Technology Adoption Trends Across B-Cell Depletion, BAFF-R Targeting, BLyS/APRIL Inhibition, FcRn Blockade, Immune Co-Stimulation Modulation, Secretagogues, and Ophthalmic Therapies List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Syndrome Type, Drug Class, Route of Administration, and Distribution Channel (2025 vs. 2032) Global Sjögren’s Syndrome Treatment Ecosystem and Value Chain Analysis